NASDAQ:TPTXTurning Point Therapeutics Stock Price, Forecast & News

Turning Point Therapeutics' stock was trading at $40.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TPTX stock has increased by 53.0% and is now trading at $62.03. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Turning Point Therapeutics.

Turning Point Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Turning Point Therapeutics.

Turning Point Therapeutics (NASDAQ:TPTX) posted its earnings results on Tuesday, May, 12th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($0.66) by $1.03. View Turning Point Therapeutics' earnings history.

8 equities research analysts have issued 1-year target prices for Turning Point Therapeutics' stock. Their forecasts range from $56.00 to $90.00. On average, they expect Turning Point Therapeutics' stock price to reach $71.63 in the next year. This suggests a possible upside of 15.5% from the stock's current price. View analysts' price targets for Turning Point Therapeutics.

News stories about TPTX stock have been trending extremely negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Turning Point Therapeutics earned a coverage optimism score of -4.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the stock's share price in the next few days. View the latest news about Turning Point Therapeutics.

Turning Point Therapeutics saw a decline in short interest in the month of June. As of June 15th, there was short interest totaling 2,740,000 shares, a decline of 16.2% from the May 31st total of 3,270,000 shares. Based on an average daily volume of 412,300 shares, the days-to-cover ratio is currently 6.6 days. Approximately 9.2% of the shares of the company are short sold. View Turning Point Therapeutics' Current Options Chain.

Some companies that are related to Turning Point Therapeutics include Dr.Reddy's Laboratories (RDY), Mylan (MYL), Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Mirati Therapeutics (MRTX), PPD (SDGR), United Therapeutics (UTHR), Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB) and Reata Pharmaceuticals (RETA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include AbbVie (ABBV), Pfizer (PFE), Enterprise Products Partners (EPD), GlaxoSmithKline (GSK), GW Pharmaceuticals PLC- (GWPH), ACADIA Pharmaceuticals (ACAD), Energy Transfer LP Unit (ET), General Mills (GIS), Intel (INTC) and Johnson & Johnson (JNJ).

(TPTX) raised $167 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 9,300,000 shares at $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TPTX stock can currently be purchased for approximately $62.03.

Turning Point Therapeutics has a market capitalization of $2.23 billion. The company earns $-72,130,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Turning Point Therapeutics employs 50 workers across the globe.

The official website for Turning Point Therapeutics is www.tptherapeutics.com.

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at 858-926-5251 or via email at [email protected]